Shveta Dighe – Founder, Ascend IR

Bridging Biotech Innovation with Investor Confidence

Shveta Dighe is a visionary investor relations leader with a track record of transforming biotech companies into market-recognized innovators. With deep expertise in capital markets, corporate messaging, and investor engagement, she has been instrumental in shaping the financial narratives of both publicly traded and emerging biotech companies.

As Founder of Ascend IR, Shveta partners with biotech companies to elevate their investor relations strategy, amplify market visibility, and drive long-term shareholder value. She brings a rare combination of financial acumen, scientific depth, and strategic storytelling—ensuring that groundbreaking biotech advancements are communicated with clarity and impact to investors, analysts, and stakeholders.

Proven Leadership in Investor Relations & Capital Markets

Before founding Ascend IR, Shveta led Investor Relations at Carisma Therapeutics, where she designed and executed the company’s IR strategy, built strong relationships with institutional investors/sell-side analysts, and crafted high-impact corporate messaging. Prior to that, she was Director of Investor Relations at Bristol Myers Squibb, where she played a pivotal role in shaping IR communications, financial strategy, and competitive market positioning.

Bringing a Wall Street perspective, Shveta was a Senior Equity Research Associate at Wedbush Securities, covering small- and mid-cap biotech companies. In this role, she provided actionable investment recommendations, financial modeling, and deep scientific insights, helping investors navigate the complexities of clinical-stage assets.

Education

  • MBA, Finance – Columbia Business School, New York, NY (Class of 2014)

  • MS, Pharmacology – St. John’s University, Queens, NY (Class of 2008)

  • B. Pharm. – Bombay College of Pharmacy, Mumbai, India (Class of 2005)

At Ascend IR, Shveta is committed to helping biotech innovators secure funding, enhance market visibility, and establish credibility with investors. Her hands-on, strategic approach ensures that emerging biotech companies can navigate the public markets with confidence and clarity.